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Abstract
We made an H1N1 vaccine candidate from a virus library consisting of 144 (=16 HA69 NA) non-pathogenic influenza A
viruses and examined its protective effects against a pandemic (2009) H1N1 strain using immunologically naı ¨ve cynomolgus
macaques to exclude preexisting immunity and to employ a preclinical study since preexisting immunity in humans
previously vaccinated or infected with influenza virus might make comparison of vaccine efficacy difficult. Furthermore,
macaques carrying a major histocompatibility complex class I molecule, Mafa-A1*052:02, were used to analyze peptide-
specific CD8
+ T cell responses. Sera of macaques immunized with an inactivated whole particle formulation without
addition of an adjuvant showed higher neutralization titers against the vaccine strain A/Hokkaido/2/1981 (H1N1) than did
sera of macaques immunized with a split formulation. Neutralization activities against the pandemic strain A/Narita/1/2009
(H1N1) in sera of macaques immunized twice with the split vaccine reached levels similar to those in sera of macaques
immunized once with the whole particle vaccine. After inoculation with the pandemic virus, the virus was detected in nasal
samples of unvaccinated macaques for 6 days after infection and for 2.67 days and 5.33 days on average in macaques
vaccinated with the whole particle vaccine and the split vaccine, respectively. After the challenge infection, recall
neutralizing antibody responses against the pandemic virus and CD8
+ T cell responses specific for nucleoprotein peptide
NP262-270 bound to Mafa-A1*052:02 in macaques vaccinated with the whole particle vaccine were observed more
promptly or more vigorously than those in macaques vaccinated with the split vaccine. These findings demonstrated that
the vaccine derived from our virus library was effective for pandemic virus infection in macaques and that the whole particle
vaccine conferred more effective memory and broader cross-reactive immune responses to macaques against pandemic
influenza virus infection than did the split vaccine.
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Introduction
A pandemic (2009) H1N1 influenza A virus has been
transmitted among humans since April 2009 [1]. We revealed
that the pandemic (2009) H1N1 virus replicated efficiently in non-
human primates and caused more severe pathological changes in
the lungs of infected macaques than did a circulated human H1N1
(Russian flu) virus [2]. A substantial number of hospitalized
individuals did not have underlying health issues during the
pandemic [3,4], and their symptoms were as severe as those seen
in cynomolgus macaques [2,5,6]. In addition, cynomolgus
macaques are susceptible to other unadapted human influenza
viruses after minimal passages in cell culture for isolation of the
virus [7]. Since the clinical symptoms seen in cynomolgus
macaques infected with influenza viruses closely reflect the signs
of disease observed in humans, cynomolgus macaque models of
influenza virus infection are useful for predicting symptoms and
extrapolating pathogenesis in humans. Therefore, we examined
the efficacy of vaccines against pandemic (H1N1) 2009 influenza
virus using macaques.
In the present study, we selected a vaccine strain from a non-
pathogenic influenza A virus library that contains 144 different
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37220combinations of 16 hemagglutinins (HA) and 9 neuraminidases
(NA) subtypes, and we examined the efficacy of the vaccine [8–
11], and then compared differences in formulations of vaccines,
whole particle vaccines and split vaccines. Although the efficacy of
whole particle vaccines has been described previously in humans
[12], it is difficult to exclude disturbance of pre-existing immunity
due to previous infection with influenza viruses [2,13,14]. We used
immunologically naı ¨ve non-human primates to test the vaccine
efficacy with focus on induction of memory cytotoxic T
lymphocyte (CTL) responses. In addition, animal models enable
examination of the time lag between infection with a virus and
initiation of immune responses, which is shorter in recall memory
responses than in primary responses. Thus, non-human primates
would be excellent tools to examine memory responses after
vaccination.
A problem in studies using non-human primates is the
difficulty in searching for epitopic peptides in individual animals
to analyze peptide-specific T cell responses since major
histocompatibility complex (MHC) genes are polymorphic and
most of the macaques used for biomedical research are not inbred
strains [15–18]. To solve this problem and to precisely analyze
CTL responses specific for influenza virus peptides in macaques,
we used macaques expressing Mafa-A1*052:02, which was
observed at a frequency of 17% in the Mafa-A1 allele of
cynomolgus macaques originating from the Philippines (Shiina et
al., unpublished data).
To examine peptide-specific memory CTL responses, a Mafa-
A1*052:02- binding motif and epitopes of nucleoprotein (NP) of
the pandemic virus were determined using two approaches. Firstly,
we used a peptide-binding assay with overlap peptides. These
peptides were mixed with cells lacking transporter associated with
antigen processing (TAP) proteins, which do not present endog-
enous cytosolic peptides on MHC class I molecules or do not allow
stable expression of MHC class I molecules on the cell surface
unless appropriate exogenous peptides are added [19,20].
Therefore, binding of peptides to MHC class I is detected as
stable expression of MHC class I molecules. Secondly, we
identified naturally processed peptides eluted from MHC mole-
cules using liquid chromatography with tandem mass spectrometry
(LC-MS/MS) and a genetic information database as previously
described [21]. Consequently, we determined NP peptides that
bound to Mafa-A1*052:02.
Recall memory CTL responses specific for NP peptides in
lymph node cells from macaques immunized with the whole
particle vaccine were more vigorous than those in lymph node
cells from macaques immunized with the split vaccine. Further-
more, recall neutralization antibody responses against the
pandemic challenge strain in macaques vaccinated with the
whole particle vaccine were observed more promptly than those
in macaques vaccinated with the split vaccine. Therefore, the
results suggest that the inactivated whole particle vaccine is more
effective against pandemic influenza virus infection than is the
split vaccine, inducing cross-reactive memory CTL and antibody
responses.
Results
Antibody Responses After Inoculation of an Inactivated
Whole Virus Particle Vaccine or a Split Vaccine Prepared
from a Non-pathogenic H1N1 Strain in a Virus Library
To compare immune responses in different vaccine formula-
tions, we prepared an inactivated whole viral particle vaccine and
a split vaccine using the A/swine/Hokkaido/2/1981 (H1N1)
(Hokkaido2) strain that was selected from our virus library
previously described [8]. The vaccine was subcutaneously
inoculated twice into each macaque, and antibody responses in
the vaccinated macaques were examined during a 7-week period
between the second vaccination and challenge with an H1N1
pandemic virus. The macaques showed no systemic symptoms
after the vaccination. No skin reaction at the site of injection was
observed after inoculation with either the whole particle vaccine or
split vaccine.
Serum IgM specific for Hokkaido2 antigen was clearly detected
in 2 of the 3 macaques vaccinated with the whole particle vaccine
one week after the first vaccination and in all macaques
vaccinated with the whole particle vaccine 2 weeks after the first
vaccination (before the second vaccination that was performed 2
weeks after the first vaccination) (Fig. 1A). In the 3 macaques
vaccinated with the whole particle vaccine, serum total IgG, IgA,
and IgG1 specific for Hokkaido2 were detected 2 weeks after the
first vaccination and production of IgG1 antibody was enhanced
after the second vaccination (Fig. 1B–D). Antigen-specific
antibody levels gradually declined from 2 weeks after the second
vaccination. On the other hand, serum IgM, IgG, IgA and IgG1
responses specific for Hokkaido2 in macaques vaccinated with the
split vaccine were lower than those in macaques vaccinated with
the whole particle vaccine (Fig. 1A–D). Antigen-specific IgG
antibodies in nasal swab samples from all of the macaques
vaccinated with the whole particle vaccine and 2 of the 3
macaques vaccinated with the split vaccine (except #750) were
detected 2 weeks after the first vaccination (Fig. 1E). Antigen-
specific IgA was detected in swab samples from 2 macaques
vaccinated with the whole particle vaccine (#312 and #784) and
in swab samples from all 3 macaques vaccinated with the split
vaccine (Fig. 1F).
Next, we examined neutralization activity of serum antibody
from macaques vaccinated with the whole particle or the split
vaccine. Sera from macaques vaccinated with the whole particle
vaccine showed significantly higher neutralization activity
against Hokkaido2 than did sera from macaques inoculated
with the split vaccine from week 2 to week 8 (P,0.05) (Fig. 2A)
and less potent neutralization activity against the pandemic
strain A/Narita/1/2009 (H1N1) pdm (Narita1) [22,23] than
against Hokkaido2 (Fig. 2B). Sera from two macaques vacci-
nated with the split vaccine 2 weeks after the first vaccination
showed no detectable neutralization activity against Narita1.
Sera from two macaques (#729, #742) vaccinated with the split
vaccine 2 weeks after the second vaccination (week 4) showed
neutralization activity against Narita1 at a level comparable to
that in sera from macaques vaccinated once with the whole
particle vaccine (week 2). The average of 50% neutralization
titers against Narita1 in sera from macaques vaccinated with the
whole particle vaccine was significantly higher than that in sera
from macaques vaccinated with the split vaccine in week 8
(P,0.05) (Fig. 2B). These results suggested that a single
vaccination with a whole particle vaccine has potency similar
to that of two inoculations with split vaccines in serum
neutralization activity.
T lymphocyte Responses Specific for Vaccine Antigens
After the Second Vaccination in Cynomolgus Macaques
Two weeks after the second vaccination (week 4), cytokine
production by T lymphocytes specific for the vaccine antigen was
analyzed. CD4
+ and CD8
+ T cells from all macaques vaccinated
with the whole particle vaccine produced interferon (IFN)-c and
interleukin (IL)-2 (Fig. 3). In contrast, T cells from macaques
vaccinated with the split vaccine produced smaller amounts of
IFN-c and IL-2 than did those from macaques vaccinated with the
Vaccine against Pandemic Influenza in Macaques
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37220Figure 1. Antibody responses specific for H1N1 vaccine antigens in vaccinated cynomolgus macaques. Cynomolgus macaques were
subcutaneously immunized twice (in weeks 0 and 2) with a whole virus particle vaccine (#312, #775 and #784, orange symbols) or with a split
vaccine (#729, #742 and #750, blue symbols) derived from Hokkaido2. Sera and swab samples were collected in indicated weeks after the first
vaccination. IgM (A), IgG (B, E), IgA (C, F), and IgG1 (D) antibodies specific for Hokkaido2 antigens in sera (A-D) and nasal swab samples (E, F) were
analyzed using ELISA. Optical densities at 450 nm are shown. In IgM and IgA measurements (A, C, F), the OD450 values before vaccination as non-
specific background responses were subtracted from those after vaccination.
doi:10.1371/journal.pone.0037220.g001
Figure 2. Neutralization activity of sera in the vaccinated cynomolgus macaques. Sera were collected in the indicated weeks after the first
vaccination. Sera of week 2 were obtained before the second vaccination. The neutralization titers against Hokkaido2 (A) and Narita1 (B) were
expressed as reciprocals of dilution of the serum samples that showed CPE in 50% of the wells. Detection limits were 1:8 in week 0 and 1:4 in the
other weeks. P values calculated with Student’s t-test are less than 0.05 in comparison between the whole particle vaccine group and split vaccine
group against Hokkaido2 and Narita1 (*) when the titers below 1:4 are calculated as 1:4.
doi:10.1371/journal.pone.0037220.g002
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whole particle antigen, though the differences were not statistically
significant. These results indicated that subcutaneous vaccinations
with the whole particle vaccine induced greater T cell responses,
especially Th1 type responses in both CD4
+ and CD8
+ T cells,
than did the split vaccine, as well as IgG1 antibody responses
(Fig. 1), which are assisted by Th1 cells in humans.
Protective Effects of Two Formulations of the Inactivated
Vaccine Against a Pandemic (H1N1) 2009 Strain in
Cynomolgus Macaques
Next, to examine efficacy of the vaccines, the pandemic (H1N1)
2009 virus strain, Narita1, was inoculated into nasal cavities of
macaques 7 weeks after the second vaccination. Body temperature
was expressed by calculating the average of the highest and lowest
Figure 3. Cytokine production by T lymphocytes from the vaccinated macaques. CD8
+ cells (A, B) and CD4
+ cells (C, D) were separated
from the blood cells 2 weeks after the second vaccination (week 4). T lymphocytes were cultured with irradiated APC and the whole particle or split
vaccine antigen (10 mg/ml) for 48 h. Culture without antigen is indicated as medium. Cytokines (IFN-c; A, C, IL-2; B, D) in the supernatants were
measured with a multiple cytokine array. IL-4 production was under the detection limit.
doi:10.1371/journal.pone.0037220.g003
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challenge was compared with that before the virus challenge.
When we focused on temperature changes until day 7 after
infection, higher body temperature than that before the challenge
was observed for 7 to 8 days after infection in the unvaccinated
macaques (7.67 days on average, Fig. 4, left panels), while raised
body temperatures in the macaques vaccinated with the whole
particle vaccine and in macaques vaccinated with the split vaccine
were observed for 2 to 8 days (5 days on average, Fig. 4, middle
panels) and 6 to 7 days (6.33 days on average, Fig. 4, right panels),
respectively, though differences among the three groups were not
statistically significant. Therefore, these results indicated a
tendency for vaccination with inactivated Hokkaido2 to accelerate
recovery of body temperature and reduce morbidity caused by
infection with the pandemic influenza virus. No macaques either
with or without vaccination lost weight or appetite after
inoculation with Narita1 (data not shown).
We examined the virus titers in swab samples after challenge
with the pandemic virus Narita1. The virus was detected in swab
samples from nasal cavities of the unvaccinated macaques for 6
days (6 days on average) and in swab samples from tracheas for 3
to 5 days (4.33 days on average) after inoculation with Narita1
(Fig. 5A, D). On the other hand, in the macaques vaccinated with
the whole particle vaccine, the virus was detected until day 5 (3.67
days on average) in nasal samples and until day 4 (3.67 days on
average) in tracheal samples (Fig. 5B, E). The virus in nasal and
tracheal samples of macaques vaccinated with the split vaccine was
detected until day 6 (5.33 days on average) and until day 3 (3 days
on average), respectively (Fig. 5C, F). The average areas under the
curves (AUC) of virus titers were 16.6, 4.37 and 13.4 log10T-
CID50/mlNday in nasal samples and 4.50, 2.30 and 3.95
log10TCID50/mlNday in tracheal samples of macaques inoculated
with saline, the whole particle vaccine and the split vaccine,
respectively. Significant differences of virus titer AUC in nasal
samples were observed between the saline group and whole
particle vaccine group (P=0.016) and between the whole particle
vaccine group and split vaccine group (P=0.03). Therefore,
inoculation with the whole particle vaccine of Hokkaido2 derived
from the non-pathogenic virus library interfered with propagation
of the pandemic strain Narita1 in the upper respiratory tracts
more effectively than did inoculation with the split vaccine.
Memory Antibody Responses after Challenge Infection
with the Pandemic Influenza Virus
We examined recall antibody responses against the vaccine
strain Hokkaido2 and the pandemic strain Narita1 after challenge
infection. In the sera from macaques without vaccination,
neutralization activity against Hokkaido2 and Narita1 was
detected 6 to 10 days after challenge infection with Narita1
(Fig. 6A, D). Neutralization activity against Hokkaido2 and
Narita1 was observed in the sera from macaques vaccinated with
the whole particle vaccine before the challenge infection (day 0)
(Fig. 6B, E), and neutralization titers against Narita1 were
increased 2 days after the challenge, suggesting that the challenge
infection induced immediate recall antibody responses against
Narita1.
Figure 4. Body temperatures of macaques after inoculation of the pandemic (H1N1) 2009 influenza virus. Cynomolgus macaques were
subcutaneously immunized with the whole particle vaccine (middle column) or with the split vaccine (right column). Cynomolgus macaques injected
with saline were used as unvaccinated controls (left column). On day 0, 7 weeks after the second vaccination, Narita1 (2610
5 TCID50) was inoculated
into nasal cavities of the macaques. Lines horizontally drawn indicate average temperature levels at pre-infection.
doi:10.1371/journal.pone.0037220.g004
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with the split vaccine was observed against Hokkaido2 but not
against Narita1 before the challenge infection, and neutralization
activity against Hokkaido2 was increased on days 4 to 6 after the
challenge (Fig. 6C, F). On the other hand, neutralization activity
against Narita1 was increased on days 8 to 10 in sera from
macaques vaccinated with the split vaccine and was significantly
lower on day 4 and day 6 than that with the whole particle vaccine
(P,0.05). These responses were similar to responses observed in
the unvaccinated macaques. These findings indicate that vaccina-
tion with the whole particle vaccine generated immunological
memory in B cells that produced antibodies against not only the
vaccine strain but also the challenge strain (i.e., crossreaction),
whereas vaccination with the split vaccine induced memory B cell
responses against the vaccine antigens but not against the antigens
of the challenge strain.
Identification of Nucleoprotein Peptides that Induced
Mafa-A1*052:02-restricted CD8
+ T cell Responses After
Challenge with the Pandemic (H1N1) 2009 Strain
Next, we examined memory CTL responses in macaques
vaccinated with the whole particle vaccine and the split vaccine.
To measure antigen-specific CTL responses, we used macaques
carrying an MHC class I molecule, Mafa-A1*052:02 (Table 1).
Furthermore, we prepared 10-mer influenza virus peptides derived
from NP, which overlapped 5 amino acids in consecutive peptides
and showed amino acid sequences of some peptides since NP was
shown in mice to be a nuclear/cytosolic target antigen for CTL
(Fig. 7A). Firstly, we determined peptides bound to Mafa-
A1*052:02. To perform a peptide binding assay, we established
an RMA-S cell line that lacked TAP-2 protein for presentation of
endogenous peptides and expressed Mafa-A1*052:02 and human
b2-microglobulin for presentation of exogenous peptides. Using
the RMA-S transfectant, we found that 3 NP peptides (#16, #53
and #74) bound to Mafa-A1*052:02 (Fig. 7B). NP#44 showed a
weak binding capacity to Mafa-A1*052:02 on the surface of the
RMA-S transfectant.
We cultured CD8
+ T cells from Narita1-infected macaques with
the NP peptides and measured IFN-c responses. IFN-c production
was detected in the culture of CD8
+ T cells from macaques
vaccinated with the whole particle vaccine with NP#44, #45,
#53 and #74 and from macaques vaccinated with the split
vaccine with NP#12, #16, #37, #44, #53 and #74 (Fig. 7C).
Since IFN-c production by stimulation with NP#53 was
observed in the culture of cells from all vaccinated macaques
(Fig. 7C), we performed further analyses of the NP#53 peptide. A
peptide lacking C-terminal residue 270 (NP261-269) lost binding
capacity to Mafa-A1*052:02 (Fig. 8A, B), suggesting that the
residue 270 V was one of the anchor residues. Furthermore,
deletion of residue 261 enhanced binding of the peptide (NP262-
270) to Mafa-A1*052:02, and NP263-270 showed binding to
Mafa-A1*052:02 similar to that of NP261-270, suggesting that
Figure 5. Virus recovery from macaques inoculated with Narita1. Each macaque was inoculated with Narita1 on day 0 (saline: A, D; whole
particle vaccine, B, E; split vaccine, C, F). Virus titers in nasal (A-C) and tracheal (D-F) swab samples were determined using MDCK cells. Virus titers
were under detection limit after day 7.
doi:10.1371/journal.pone.0037220.g005
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Henceforth, we used NP262-270 as a basic peptide bound to
Mafa-A1*052:02. Deletion of residue 263 impaired binding to the
Mafa-A1*052:02 transfectant, indicating that position 263 was one
of the anchor residues or that it affected binding capacity.
To determine the precise anchor residues, we used a series of
peptides of which amino acids were substituted (Fig. 8C).
Substitutions at residues 264, 266 and 270 diminished binding
of peptides to Mafa-A1*052:02 (Fig. 8D), suggesting that residues
264 (position 3 from the N-terminus), 266 (position 5) and 270
(position 9) were anchor residues that were essential for
presentation on Mafa-A1*052:02 and that L at position 3, L at
position 5 and V at position 9 comprised a binding motif for Mafa-
A1*052:02. Substitutions at residues 263, 265 and 267 had weak
effects on the binding of peptides to Mafa-A1*052:02.
We examined sequences of naturally processed peptides bound
to Mafa-A1*052:02 using a 721.221 transfectant established by
introduction of a Mafa-A1*052:02 gene into an MHC null human
B cell line and LC-MS/MS [21]. In analyses of peptides eluted
from Mafa-A1*052:02 with 9 to 12 amino acids in length,
hydrophobic residues were observed at position 9 when C-
terminal residues were aligned as position 9 (Table 2). In addition,
leucine or isoleucine was detected at position 5 in 8 of the 15
peptides, and leucine, isoleucine or valine was detected at position
3 in 4 of the 15 peptides. This motif was compatible with the
sequence of NP262-270 (SALILRGSV).
Memory T Cell Responses After Challenge with the
Pandemic (H1N1) Strain in Vaccinated Macaques
Finally, we examined CD8
+ T cell responses against NP262-270
using cervical lymph node cells of the infected macaques. IFN-c
production in CD8
+ T cells was observed after culture with
NP262-270 and restimulation (Fig. 9A). The percentage of IFN-c-
producing cells in CD8
+ T cells stimulated in vitro with NP262-270
from macaques vaccinated with the whole particle vaccine (48.3%
on average) was significantly higher than the percentage of those
from macaques vaccinated with saline (24.6% on average,
P=0.034 in saline vs. whole particle vaccine) and with the split
vaccine (21.7% on average, P=0.049 in whole particle vaccine vs.
split vaccine) (Fig. 9B). Since IFN-c production in CD8
+ T cells
from the macaques inoculated with saline was the primary
response with Narita1 infection, the higher percentage of IFN-c-
producing CD8
+ T cells in the whole particle group than that in
the saline group seemed to indicate memory responses induced by
vaccination. These responses were likely to be memory recall
responses since the recall responses in macaques inoculated with
the whole particle vaccine were examined 7 weeks after the
vaccination. In contrast, there was no significant difference in the
percentage of IFN-c-producing CD8
+ cells between the saline
group and split vaccine group (Fig. 9B), though IFN-c production
level per cell (mean fluorescense intensity) in the split vaccine
group was higher than that in the saline group (Fig. 9A). These
results indicated that the whole particle vaccine more effectively
generated memory T cells than did the split vaccine.
Figure 6. Neutralization activities of serum samples after infection with Narita1. Cynomolgus macaques were vaccinated with saline (A, D),
whole particle vaccine (B, E), or split vaccine (C, F) as described in the legend to Fig. 1. Macaques were inoculated with Narita1 as described in the
legend to Fig. 4. Sera were collected on indicated days after the challenge infection. Fifty percent neutralization titers against Hokkaido2 (A-C) and
Narita1 (D-F) were determined. Statistically significant differences of average neutralization titers between the whole particle vaccine group and split
vaccine group are indicated with asterisks (P,0.05 with Student’s t-test).
doi:10.1371/journal.pone.0037220.g006
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37220Figure 7. NP peptides bound to Mafa-A1*052:02. (A) Amino acid sequences of 10-mer peptides derived from Narita1 nucleoprotein are shown
as one-letter code. The sequence of influenza A virus PB1 peptide was used as a representative of non-binding peptides to Mafa-A1*052:02. The
numbers in parentheses indicate residues from the N-terminus of NP. (B) RMA-S expressing Mafa-A1*052:02 and human b2-microglobulin was
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We examined antibody and T cell responses induced by
subcutaneous vaccination with two forms of preparation, whole
particle vaccine and split vaccine, using immunologically naı ¨ve
cynomolgus macaques for influenza virus infection. The macaque
model enabled evaluation of vaccine efficacy without consider-
ation of pre-existing immunity, which has been difficult to exclude
in human studies [2,13,14]. Since most inactivated vaccines are
inoculated subcutaneously or intramuscularly in humans [14,24],
we subcutaneously inoculated vaccines into macaques to reflect
results in the present study to human vaccination usage. As a
result, the whole particle vaccine derived from our virus library
was more effective for conferring memory immune responses and
prohibiting virus replication than was the split vaccine.
We previously revealed that pandemic (H1N1) 2009 influenza
virus caused viral pneumonia in cynomolgus macaques, which
resembled pneumonia in human patients during the pandemic [2–
6]. Furthermore, we were able to analyze immune responses in
macaques using antibodies against human molecules [25], whereas
reagents for immunological analyses were not sufficient in ferrets
that showed human-like clinical symptoms by human influenza
viruses. Therefore, we considered the macaque models to be
suitable for extrapolation of responses and efficacy of vaccines
against pandemic influenza virus infection in humans.
As shown in Fig. 7C, CD8
+ T cells of individual vaccinated
macaques responded to different sets of NP peptides since the
macaques used in the present study were not inbred. To compare
peptide-specific T cell responses between two vaccinations, we
required a parameter shared by all studied macaques. Therefore,
we selected macaques carrying Mafa-A1*052:02 and identified
NP262-270 as a peptide that induced CD8
+ T cell responses in all
vaccinated macaques. The variety of stimulatory peptides except
NP262-270 among macaques might be due to antigen presenta-
tion on other Mafa class I molecules, i.e., the second allelic product
of Mafa-A1 other than Mafa-A1*052:02 and Mafa-B (Table 1).
Therefore, we examined CD8
+ T cell responses specific for
NP262-270 plus Mafa-A1*052:02 to compare memory T cell
responses in macaques vaccinated with the whole particle vaccine
with those in macaques vaccinated with the split vaccine.
One of the peptides that bound to Mafa-A1*052:02, NP#74,
contained a known CTL epitope (ASNENVETM, NP366-374)
bound to mouse MHC class I H-2D
b, in which N at position 5 and
M at position 9 are known as main anchor residues and N at
position 3 is a minor anchor [26]. The results presented in Fig. 8
showed that anchor positions of NP262-270 were aligned with the
same intervals as those seen in NP366-374 bound to H-2D
b.
Therefore, it is possible that the Mafa-A1*052:02 binding motif is
similar to that of H-2D
b, i.e., hydrophobic or non-polar residues at
positions 3, 5 and 9. This was supported by analyses of peptides
eluted from Mafa-A1*052:02 (Table 2). Based on these results, the
Mafa-A1*052:02 binding motif appeared to be hydrophobic
residues (L, I or V) at position 3, hydrophobic residues (L or I)
at position 5 and hydrophobic or aromatic residues (L, V, M, F or
Y) at position 9 as anchors.
Using macaques carrying Mafa-A1*052:02, we showed advan-
tages of the whole particle vaccine in three aspects, immunological
memory, immunogenicity and cross-reactivity. Firstly, we proved
the advantage of the whole particle vaccine in memory CTL
responses. A higher percentage of IFN-c-positive CD8
+ cells
specific for the NP262-270 peptide was observed in macaques
vaccinated with the whole particle vaccine than in macaques
without vaccination and macaques vaccinated with the split
vaccine (Fig. 9). Therefore, it is thought that memory T cells were
maintained in macaques inoculated with the whole particle
vaccine and expanded promptly after challenge infection.
The whole particle vaccine also induced immunological
memory in antibody responses more effectively than did the split
vaccine. Neutralizing activity of sera against the challenge strain
increased 2 days after the challenge infection in macaques
vaccinated with the whole particle vaccine, whereas increase of
neutralization activity against the challenge strain in sera from
macaques vaccinated with the split vaccine was detected on days 8
to 10 after challenge infection (Fig. 6). This was only 2 days earlier
than that in macaques without vaccination. Therefore, the whole
particle vaccine generated immunological memory in both cellular
and humoral responses more effectively than did the split vaccine.
Since recall memory B cell responses were impaired in MyD88-
deficient mice, Toll-like receptors (TLR) stimulated by whole
particle vaccines would play a critical role in generation of
memory B cells [27].
Secondly, as previously shown in mouse and human studies
[28–30], the whole particle vaccine induced higher titers of
neutralizing antibody in macaques than did the split vaccine
(Fig. 2). This indicates that inactivated whole viral particles were
more immunogenic than soluble split antigens in macaques.
Several studies have indicated that a virus-like particle (VLP)
antigen was superior to a soluble protein in inducing Th1 and
CTL responses with effective antigen cross-presentation by
dendritic cells [31–33]. We also showed that one immunization
with the whole particle vaccine induced neutralizing antibody at a
level similar to that induced by two immunizations with the split
vaccine. This result suggests that we could reduce the dose of
vaccination by using whole particle vaccines to save vaccine
amounts and distribute vaccines to more people than by using split
vaccines.Not only formulation of antigens but also additional
cultured with NP peptides at 27uC for 1 h and then at 37uC for 4 h. Stable expression of Mafa-A1*052:02 on the cell surface was examined by staining
with W6/32 antibody. Orange lines: cells cultured with indicated peptides. Blue shade: cells cultured without peptide. (C) CD8
+ cells were isolated
from spleens of indicated macaques and cultured with APC and indicated peptides. IFN-c production was determined using ELISA. Averages and SD
of triplicate culture are shown. Representative results of three independent experiments are shown.
doi:10.1371/journal.pone.0037220.g007
Table 1. Mafa-A1 alleles of macaques used in the present
study.
Mafa-A1
Animal ID Allele 1 Allele 2
785 052:02 089:03
848 052:02 089:03
994 052:02 008:02
312 052:02 004:01
775 052:02 093:01
784 052:02 089:03
729 052:02 094:01
742 052:02 093:02
750 052:02 094:01
doi:10.1371/journal.pone.0037220.t001
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affect the immunogenicity. IL-12 and tumor necrosis factor (TNF)-
a production by human dendritic cells was enhanced by whole
particle vaccines but not by subunit vaccines [34]. This response
might be partly mediated by TLR signals [35]. Inactivated whole
virus particles showed adjuvant effects by activating the TLR7-
MyD88 pathway in plasmacytoid dendritic cells [36]. Type I
interferon production by plasmacytoid dendritic cells was crucial
for induction of primary B cell and CD4
+ T cell responses and
cross-presentation of antigen by dendritic cells, resulting in
Figure 8. A core sequence and anchor residues of NP#53 peptides bound to Mafa-A1*052:02. (A) Amino acid sequences of truncated
NP#53 peptides. (B) Truncated NP#53 peptides were cultured with the Mafa-A1*052:02 transfectant as described in the legend to Fig. 7. Orange:
cells cultured with truncated NP#53 indicated in each histogram. Green: cells cultured with untruncated NP#53 (261–270). Blue: cells cultured
without peptide. (C) Amino acid sequences of substituted NP262-270 peptides. Amino acids of NP262-270 were substituted to alanine except residue
263 that was substituted to glycine. (D) Substituted NP262-270 peptides were cultured with the Mafa-A*052:02 transfectant. Orange: cells cultured
with substituted NP262-270 indicated in each histogram. Green: cells cultured with unsubstituted NP262-270. Blue: cells cultured without peptide.
Representative results of three independent experiments are shown.
doi:10.1371/journal.pone.0037220.g008
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signal also stimulated naı ¨ve B cells directly and enhanced B cell
responses [39,40]. Concordant with the previous reports, we
showed that IgG1 responses, one of the hallmarks of Th1
responses in human immune responses, were induced more
effectively in cynomolgus macaques after vaccination with the
whole particle vaccine than with the split vaccine (Fig. 1),
indicating that whole particle vaccines including virus RNA as a
natural adjuvant enhanced immunogenicity and induced Th1
responses [28,41,42]. Therefore, whole particle vaccines do not
necessarily need inoculation with an additional adjuvant.
Thirdly, sera from macaques inoculated with the whole particle
vaccine showed neutralizing activity against not only the vaccine
strain but also the challenge strain (Figs. 2 and 6), resulting in
lower virus titers after challenge in macaques vaccinated with the
whole particle vaccine than in macaques vaccinated with the split
vaccine (Fig. 5). In the present study, similarities of HA and NA
between the vaccine strain and the challenge virus strain were
89% and 83% at the amino acid level, respectively. These results
indicated that whole particle vaccines induced not only a larger
amount of specific antibody but also a more broadly cross-reactive
antibody than did split vaccines [43]. This might be explained by
results of previous studies showing that whole particle vaccines and
split vaccines activated different B cell repertoires (clones) [44] and
that two formulations of vaccines induced differentiation of distinct
T helper cells such as Th1 and Th2 as discussed above, resulting in
differences in the number of reacting B cells and affinity
maturation [28,45]. Furthermore, since sequences of NP including
CTL epitopes were conserved in influenza A viruses compared
with HA and NA, CTL specific for NP and other internal proteins
might react to heterosubtypic influenza viruses [46,47]. Thus,
whole particle vaccines would be effective even if viral antigens
were changed by gene mutations within a certain range.
Therefore, our virus library containing 144 combinations of
16 HA and 9 NA would be useful when pandemic vaccines are
prepared as whole particle vaccines to induce both antibody and
CTL responses with broad cross-reactivity [8].
In summary, we showed that inactivated whole virus particles
from the virus library were effective against pandemic (H1N1)
2009 influenza virus infection using the cynomolgus macaque
model. Whole particle vaccines were superior for induction of
memory antibody and CTL responses, which were confirmed at
the level of peptide-specific responses. We are examining other
Mafa class I and class II types and we are breeding macaques
carrying specific MHC haplotypes. These macaques will be useful
for evaluation of vaccination and analysis of both cellular and
humoral immune responses in future studies.
Materials and Methods
Animals and Ethics Statement
?This study was carried out in strict accordance with the
Guidelines for the Husbandry and Management of Laboratory
Animals of Research Center for Animal Life Science at Shiga
University of Medical Science and STANDARDS RELATING
TO THE CARE AND MANAGEMENT, ETC. OF EXPERI-
MENTAL ANIMALS (Notification No.6, March 27, 1980 of the
Prime Minister’s Office, Japan). The protocol was approved by the
Shiga University of Medical Science Animal Experiment Com-
mittee (Permit number: 2009-5-2H) and the Biosafety Committee
(Permit number: 2009-2). The animal experiments were conduct-
ed in strict compliance with animal husbandry and welfare
regulations. All procedures were performed under ketamine and
xylazine anesthesia, and all efforts were made to minimize
suffering. Food pellets of CMK-2 (CLEA Japan, Inc., Tokyo,
Table 2. Amino acid sequences of peptides eluted from Mafa-A1*052:02.
sources NCBI accession start position MW
1 amino acid sequences
2
GI number 1 2 3 4 5 6 7 8 9
3
Guanylate cyclase soluble subunit a3 isoform A 67763816 127 1112.66 V P V E V I
4 KES L
S-adenosylmethionine synthase isoform type 2 5174529 150 1235.75 M P L T I V L AHK L
proliferation-associated protein 2G4 124494254 180 1225.62 T P I E G M L SHQ L
tudor domain containing 7 112293287 975 1296.84 R V L L K G I L TNG L
FLJ00043 protein/EH domain-binding
protein 1-like protein-1
150378549 904 980.59 A P V TQ PRV L
CAP-Gly domain-containing linker protein1/2 4506751 273/280 1250.77 A P I H K V I RI G F
SEC14-like protein 1 221316682 206 1238.74 V V I P E A A L KEG L
60 S ribosomal protein L15 15431293 83 1403.79 K P V H H G V N Q L K F
structural maintenance of chromosomes flexible
hinge domain-containing protein 1
148839305 807 1156.72 R P L P S K A I K F
mitotic checkpoint protein BUB3 4757880 11 1303.65 Q P P E D G I S S V K F
dnaJ homolog subfamily A member 1 4504511 313 1520.86 R P Y E K G R L IIE F
FH1/FH2 domain-containing protein 1 118572599 107 1182.76 K P T L I L RTQ L
intraflagellar transport protein 57 homolog 8922256 100 1193.56 R P F E Q P Q E Y
ubiquitin-conjugating enzyme E2 D4 8393719 43 1001.47 S P Y Q G G V F F
vacuolar protein sorting-associated protein 13A 66346674 2184 1043.42 T C V TS I CE M
1Molecular weight of eluted peptides.
2Amino acid sequences of peptides eluted from Mafa-A1*052:02 are shown as a one-letter code.
3C-terminals of peptides are aligned as position 9.
4Bold letters are amino acids that are compatible with the predicted Mafa-A1*052:02-binding motif.
doi:10.1371/journal.pone.0037220.t002
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water were available ad libitum. Animals were singly housed under
controlled conditions of humidity (4065%), temperature
(2561uC), and light (12 h light/12 h dark cycle, lights on at
8:00 A.M.). Five- to seven-year-old female cynomolgus macaques
from the Philippines (Ina Research Inc., Ina, Japan) were used.
The cynomolgus macaques used in the present study were healthy
young adults. In the text and figures, individual macaques are
distinguished by identification numbers. The absence of influenza
A virus NP-specific antibodies in their sera was confirmed before
experiments using an antigen-specific enzyme-linked immunosor-
bent assay (ELISA), AniGen AIV Ab ELISA (Animal Genetics
Inc., Kyonggi-do, Korea), for currently circulating influenza virus.
Two weeks before virus inoculation, a telemetry probe
(TA10CTA-D70, Data Sciences International, St. Paul, MN)
was implanted in the peritoneal cavity of each macaque under
ketamine/xylazine anesthesia followed by isoflurane inhalation to
monitor body temperature. The macaques used in this study were
Figure 9. Recall T cell responses after challenge infection with pandemic H1N1 virus. Cervical lymph node cells from the macaques 14
days after challenge with the pandemic H1N1 virus were cultured with NP262-270 peptide for 5 d. The recovered cells were stimulated with (+)o r
without (-) PMA and ionomycin for 5 h. Thereafter, intracellular IFN-c and surface CD8 were stained. (A) Representative IFN-c and CD8 profiles of each
group are shown after gating of CD8
+ cells. Upper figures: culture without PMA and ionomycin, lower figures: culture with PMA and ionomycin. Mean
fluorescence intensity (MFI) of IFN-c staining is indicated in each figure. The averages of MFI of IFN-c
+ CD8
+ cells stimulated with PMA and ionomycin
are 147, 395 and 285 in the saline group, the whole particle vaccine group and the split vaccine group, respectively. (B) The percentages of IFN-c
+
cells in CD8
+ cells are shown. The averages of percentages of three macaques in each group are indicated in the graph. There are significant
differences (P,0.05) between the saline group and whole particle vaccine group and between the whole particle vaccine group and split vaccine
group.
doi:10.1371/journal.pone.0037220.g009
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spp., Salmonella spp., and Entamoeba histolytica.
Vaccines (1 mg/dose) were inoculated subcutaneously into
macaques using syringes twice with a two-week interval between
injections under ketamine/xylazine anesthesia. Saline instead of
the vaccine was inoculated into macaques as unvaccinated
controls. The macaques were challenged with Narita1
(2610
5 TCID50/1 ml) into nasal cavities (0.5 ml for each nostril)
with pipettes 7 weeks after the second vaccinations under
ketamine/xylazine anesthesia. Experiments using Narita1 were
performed in the biosafety level 3 facility of the Research Center
for Animal Life Science, Shiga University of Medical Science.
Under ketamine/xylazine anesthesia, 2 cotton sticks (TE8201,
Eiken Chemical, Ltd., Tokyo, Japan) were used to collect fluid
samples in nasal cavities and tracheas, and the sticks were
subsequently immersed in 1 ml of PBS containing 0.1% bovine
serum albumin (BSA) and antibiotics.
Viruses and Vaccines
We used influenza virus A/swine/Hokkaido/2/1981 (H1N1)
(National Center for Biotechnology Information (NCBI) taxonomy
database ID: 387253) as a vaccine strain [48].
The Hokkaido2 virus was propagated in allantoic cavities of 10-
day-old embryonated hen’s eggs at 35uC for 48 h. To prepare an
inactivated whole particle vaccine, the allantoic fluid infected with
Hokkaido2 was concentrated and purified by high-speed centri-
fugation (112,500 g for 90 min) through a 10–50% sucrose density
gradient and then treated in 0.1% formalin at 4uC for one week
[9]. For preparation of a split vaccine, ether was mixed for 30 min
with a suspension of the viral particles purified and inactivated by
the same method as that for preparation of the whole particle
vaccine. Thereafter, ether was evaporated with bubbing at room
temperature without removal of hydrophilic solution. The amount
of the whole particle vaccine and that of the split vaccine were
indicated as the amount of entire proteins including HA and other
viral proteins. With an HA test, we confirmed that the two types of
vaccine included the same amounts of HA.
Pandemic influenza virus A/Narita/1/2009 pdm (NCBI tax-
onomy ID: 645520) was used as a challenge virus (kindly provided
by Dr. Takato Odagiri, National Institue of Infectious Disease
(NIID), Japan) [22]. In a preliminary study, we confirmed that
Narita1 inoculated into nostrils, oral cavities and tracheas caused
pneumonia in cynomolgus macaques as severe as that observed in
macaques inoculated with A/California/04/2009 (H1N1) (NCBI
taxonomy ID: 641501) [2]. Narita1 was propagated in embryo-
nated eggs twice at NIID and once in Madin-Darby canine kidney
(MDCK) cells (the American Type Culture Collection, Manassas,
VA) at the Shiga University of Medical Science [49]. The amino
acid sequence identities between Hokkaido 2 and Narita1 were
89% in HA (GI: 216409430 vs. GI: 237659680) and 83% in NA
(GI: 216409434 vs. GI: 23761745).
In order to assess virus replication, serial dilutions of swab
samples were inoculated onto confluent MDCK cells as described
previously [9]. Cytopathic effects were examined under a
microscope 72 h later.
Detection of Antibody Specific for Virus Antigen with
ELISA
The antibody titers of serum and swab samples against
Hokkaido2 antigens were determined using ELISA [50]. Ninety-
six-well plates were coated with 50 ml of purified Hokkaido2
(20 mg/ml) disrupted with 0.05 M Tris-HCl (pH 7.8) containing
0.5% Triton X-100 and 0.6 M KCl. Serially diluted samples were
incubated overnight in the coated plates. After washing five times,
horseradish peroxidase (HRP) -conjugated anti-monkey IgG
antibodies (MP Biomedicals, Inc./Cappel, Aurora, OH)
(1:2000650 ml), anti-monkey IgA antibodies (Nordic Immunolog-
ical Laboratories, Tilburg, The Netherlands) (1:4000650 ml) or
IgM (Rockland Inc., Gilbertsville. PA) (1:5000650 ml) were added
and incubated for 1 h at room temperature. For detection of IgG1,
incubation with anti-human IgG1 (clone: HP6069, Calbiochem)
(1:2000650 ml) was followed by incubation with HRP-conjugated
anti-mouse Ig (Bio-Rad Laboratories, Inc.) (1:2000650 ml). HRP
activity was assessed using 3, 39,5 ,5 9-tetramethyl benzidine
substrate (100 ml). The reaction was stopped by the addition of
1 M hydrogen chloride (100 ml). Optical density was measured at
450 nm.
Cytokine Assay
In the experiment for which results are shown in Fig. 3,
lymphocytes were purified from peripheral blood of the macaques
using a density gradient (Wako Pure Chemical Industries Ltd.,
Osaka, Japan). After washing, CD8
+ cells were isolated using CD8
microbeads for non-human primates and magnetic cell sorting
(MACS, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany),
followed by separation of CD4
+ cells using CD4 microbeads. The
cells remaining after removal of CD4
+ and CD8
+ cells were used
as antigen-presenting cells (APC) after irradiation at 30 Gy. CD4
+
or CD8
+ T cells (1610
5 cells/well) and APC (0.5610
5 cells/well)
were cultured with the inactivated whole particle antigens or the
ether split vaccine antigen in the presence of anti-CD28 (clone:
CD28.2) and CD49d (clone: 9F10) antibodies (0.5 mg/ml,
eBioscience Inc., San Diego, CA) in 96-well U-bottom plates for
48 h and supernatants were collected [10]. The concentrations of
IFN-c and IL-2 in the supernatants were measured using the
Milliplex MAP non-human primate cytokine panel and Lumi-
nex200 (Millipore Corp., Billerica, MA).
In the experiment for which results are shown in Fig. 7C, spleen
cells obtained at autopsy on day 14 after the challenge infection
were used after homogenization. After washing, CD8
+ cells were
isolated using CD8 microbeads as described above. CD8
+ T cells
(1610
5 cells/well) and APC (0.5610
5 cells/well) were cultured
with various peptides (10 mM) in the presence of anti-CD28 and
CD49d antibodies (0.5 mg/ml) in 96-well U-bottom plates for 48 h
and supernatants were collected. The concentrations of IFN-c in
the supernatants were measured by ELISA using purified anti-
human IFN-c (clone: MD-1, eBioscience) and biotinylated anti-
human IFN-c (clone: 4S.B3, BioLegend, Inc., San Diego, CA)
followed by HRP-labeled streptavidin (BD Biosciences). HRP
activity was assessed using 3, 39,5 ,5 9-tetramethyl benzidine
substrate as described above.
In the experiment for which results are shown in Fig. 9,
unfractionated cells from cervical lymph nodes obtained at
autopsy on day 14 after the challenge infection were incubated
with NP262-270 peptide (10 mM, Hokkaido System Sciences,
Sapporo, Japan) in the presence of anti-CD28, anti-CD49d
(0.5 mg/ml) and human IL-2 (10 ng/ml) for 5 d. The cultured
lymph node cells were stimulated with phorbol 12-myristate 13-
acetate (PMA) (0.1 mg/ml) and ionomycin (1 mg/ml) for 5 h.
Monensin (2 mM) was added for the last 4 h. Thereafter, cells were
washed with PBS containing EDTA (0.5 mM). Surface CD8 was
stained with fluorescein isothiocyanate (FITC)-conjugated specific
antibodies (clone: RPA-T8, eBioscience). Intracellular IFN-c was
stained with phycoerythrin (PE)-conjugated antibody (clone:
4S.B3, BD Biosciences) after fixation with 4% paraformaldehyde
and permeabilization with 0.1% saponin.
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Serum samples were pretreated with a receptor-destroying
enzyme (RDEII, Denka Seiken, Tokyo, Japan) at 37uC overnight
and then inactivated at 56uC for 1 h. The diluted samples were
mixed with 50 TCID50 of the viruses for 1 h. Then the mixture
was added onto an MDCK monolayer. After 1-h incubation, the
cells were cultured in MEM containing 0.1% BSA and 5 mg/ml
trypsin. After incubation at 35uC for 3 days, the number of wells
with cytopathic effects was counted in quadruplicate culture.
Neutralization titers were expressed as the dilution in which
cytopathic effects were observed in 50% of the wells.
Typing of Mafa-A1 and Transfection of the Mafa-
A1*052:02 Gene
Blood was collected from cynomolgus macaques and immedi-
ately mixed with Trizol (Invitrogen Corporation, Carlsbad, CA).
After extracting total RNA, cDNA was synthesized using oligo dT
primer and ReverTra Ace (Toyobo Co. Ltd., Osaka, Japan). To
amplify Mafa-A genes, PCR was performed using a set of primers
(each 0.5 mM), sense 59-GATGGCTATCATGGCGCC-39 and
anti-sense 59-TCTTCATGCCTTCTCTTTGTGACT-39, and
KOD FX polymerase (0.4 units, Toyobo) [51]. The cycling
parameters were as follows: an initial denaturation at 98uC for
1 min followed by 30 cycles of 98uC for 10 s and 68uC for 1 min.
The amplified DNA fragments were cloned into pGEM-T Easy
vector (Promega, Madison, WI). Thereafter, nucleotide sequences
were determined using an ABI3130 genetic analyzer (Applied
Biosystems, Foster City, CA) in accordance with the protocol of
the Big Dye terminator method.
The Mafa-A1*052:02 (GenBank AM943361, nomenclature
based on the WHO Nomenclature Committee for Factors of the
HLA System) gene was inserted as an EcoRI DNA fragment into
the EcoRI site of a pTA2 vector (Toyobo) and then cloned into
EcoRI sites of a pcDNA3.1
+ vector (Invitrogen). The Mafa-
A1*052:02 gene cloned in pcDNA3.1 was transfected into RMA-
S-expressing human b2-microglobulin gene (kindly provided by Dr.
Masanori Matsui) using Nucleofector Solution T and a Nucleo-
fector I device (Lonza Group Ltd., Basel, Switzerland) in
accordance with the manufacturer’s instructions. Cells that stably
expressed the introduced genes were selected with G418 (0.5 mg/
ml) and hygromycin B (0.35 mg/ml).
Peptide Binding Assay
Overlapped peptides based on the amino acid sequence of
Narita1 nucleoprotein (GenBank GQ169303, protein ID
ACR20063.1) were synthesized by the Sigma Pepscreen system
(Sigma-Aldrich Co., St. Louis, MI). Each peptide shared 5 amino
acids with consecutive peptides. RMA-S-expressing human b2-
microglobulin and Mafa-A1*052:02 genes were cultured overnight at
27uC [52,53]. Then the cells were washed twice with PBS. RMA-S
(5610
5 cells/tube) was incubated with each peptide for 30 min at
27uC and then for 4 h at 37uC. Surface Mafa-A1*052:02
molecules were detected by biotinylated W6/32 and PE-conju-
gated streptavidin (eBioscience). Dead cells were excluded by using
propidium iodide. Expression of Mafa-A1*052:02 on the cell
surface was analyzed using a flow cytometer.
Establishment of 721.221 Transfected with Mafa-
A1*052:02
pcDNA 3.1
+ vector containing Mafa-A1*052:02 gene was
introduced into an MHC class I-deficient human B cell line,
721.221 (kindly provided by Dr. Masanori Matsui), by electropo-
ration [54]. Two mg of pcDNA 3.1
+- Mafa-A1*052:02 was added
to 721.221 (2610
6 cells) in 100 ml of Nucleofector
TM Solution T
and electroporated using program A-24 on a Nucleofector I
device. G418-resistant cells were isolated.
Collection of Peptides from Mafa-A1*052:02 and LC-MS/
MS Analysis
Mafa-A1*052:02-associated peptides were purified using a
modification of a previously described protocol [21]. Briefly, one
hundred sixty 75-cm
2 flasks (BD Biosciences) of 721.221
transfectants expressing Mafa-A1*052:02 were collected and
washed twice with PBS. The cells were resuspended in ice-cold
homogenization buffer (250 mM sucrose, 20 mM HEPES-NaOH
pH 7.5). The cells were homogenized using a tight-fitting glass
dounce homogenizer. The homogenate was spun at 1,000 g for
7 min at 4uC and the supernatant was retained. The pellet was
further washed twice with homogenization buffer and the
supernatants were added to the first harvest. After centrifugation
at 12,000 g for 30 min at 4uC, the pellet was resuspended in lysis
buffer (150 mM NaCl, 20 mM Tris-HCl pH 8.0, 1% (v/v)
CHAPS solution containing protease inhibitor Cocktail (Roche
Ltd.)) for 1 h on ice. After centrifugation at 30,000 g for 1 h at
4uC, the supernatant was immunoaffinity purified with 1.7 mg of
purified antibody W6/32 coupled with 1 ml of CNBr-activated
Sepharose 4B (GE Healthcare UK Ltd., Buckinghamshire, UK)
following the manufacturer’s protocol. Bound peptides were eluted
from Mafa-A1*052:02 with 0.2 M acetic acid (pH 2.7) and were
then filtered through a Centricon 10 kDa YM-10 membrane
(Millipore Corp.) at 3,500 g for 5 h at 4uC. The filtered sample
was concentrated by a vacuum centrifuge, Savant SpeedVac SC-
100A (Thermo Fisher Scientific Inc., Waltham, MA), and
resuspended in a solution consisting of 2% acetonitrile, 0.1%
trifluoroacetic acid and 98% water. The sample was injected for
LC-MS/MS analysis.
A liquid chromatography system, Paradigm MG4 (AMR Inc.,
Tokyo, Japan), was coupled online to a linear ion trap mass
spectrometer (LTQ, Thermo Electron Corp., Waltham, MA)
equipped with an electrospray interface operated in positive ion
mode. All MS/MS spectra were identified using SEQUEST (v.28
(revision 12), Thermo Electron Corp.).
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